MIRA Pharmaceuticals, Inc
Price
FilingsNewest: 8-K, Regulation FD disclosureSep 17 →InsidersNo open-market buys. 1 insider sold $1.3M in 1 sale, with no 10b5-1 plan named.→HoldersVanguard 1.8%Cross Staff Investments 0.9%Geode 0.7%→Financing →
From the filings
Figures
- Net income
- −$9.5Mlast 12 months
- Operating cash flow
- −$4.2Mlast 12 months
- Cash and equivalents
- $3.6Mat the last balance sheet
- Shares outstanding
- 42.0M shareson issue